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Summary
Topoisomerase II creates a double-strand break intermediate
with topoisomerase covalently coupled to the DNA via a 59-
phosphotyrosyl bond. These intermediate complexes can
become cytotoxic protein-DNA adducts and DSB repair at
these lesions requires removal of topoisomerase II. To analyse
removal of topoisomerase II from genomic DNA we adapted the
trapped in agarose DNA immunostaining assay. Recombinant
MRE11 from 2 sources removed topoisomerase IIa from
genomic DNA in vitro, as did MRE11 immunoprecipitates
isolated from A-TLD or K562 cells. Basal topoisomerase II
complex levels were very high in A-TLD cells lacking full-length
wild type MRE11, suggesting that MRE11 facilitates the
processing of topoisomerase complexes that arise as part of
normal cellular metabolism. In K562 cells inhibition of MRE11,
PARP or replication increased topoisomerase IIa and b complex
levels formed in the absence of an anti-topoisomerase II drug.
 2012. Published by The Company of Biologists Ltd. This is
an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial Share Alike
License (http://creativecommons.org/licenses/by-nc-sa/3.0).
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Introduction
Human topoisomerase II is a target for important anti-cancer
drugs including etoposide, mAMSA, mitoxantrone, daunorubicin
and idarubicin (Kaufmann, 1998; Cowell et al., 2011a). The
normal catalytic cycle of topoisomerase II produces a transient
enzyme-bridged DNA double-strand break containing a covalent
protein-DNA reaction intermediate, where attachment of the
topoisomerase II to the DNA is via a 59 tyrosyl phosphodiester
linkage. Drugs such as etoposide stabilise this intermediate
resulting in dead-end complexes that can lead to cell death. Thus,
drugs that stabilise the topoisomerase-DNA complexes are
referred to as topoisomerase II poisons (Kaufmann, 1998) and
constitute a clinically important class of anti-cancer drugs.
These topoisomerase-DNA dead-end complexes can be
repaired in cells. Topoisomerase II poison-induced DSBs are
repaired predominantly through homologous recombination in
the yeast S. cerevisiae (Sabourin et al., 2003), whilst vertebrates
predominantly employ non-homologous end joining (NHEJ). The
role of NHEJ to repair topoisomerase II damage has been
demonstrated in cells from several species, including Chinese
Hamster, Chicken and Human (Jeggo et al., 1989; Caldecott et
al., 1990; Adachi et al., 2003; Adachi et al., 2004; Willmore et
al., 2004; Ayene et al., 2005). For example, we previously
reported that inhibition of the catalytic subunit of DNA
dependent protein kinase (DNA-PKcs) with the small molecule
inhibitor NU7026 massively potentiates the cytotoxicity of anti-
topoisomerase II agents such as etoposide, mitoxantrone and
mAMSA (Willmore et al., 2004).
During NHEJ, DNA dependent protein kinase (DNA-PK) is
activated by DNA breaks. However, topoisomerase-linked DSBs
do not activate DNA-PK nor bind KU in vitro (Ma˚rtensson et al.,
2003) and various lines of evidence suggest cellular processing is
required before topoisomerase-induced breaks elicit a DNA
damage response (Mao et al., 2001; Zhang et al., 2006; Fan et al.,
2008; Alchanati et al., 2009). Thus, removal of the 59
topoisomerase protein adducts from the DNA is presumably
necessary for repair of DNA breaks in vivo by NHEJ. The cellular
mechanism(s) of human topoisomerase II-DNA complex removal
are still being elucidated.
Humans possess two separately encoded type II topoisomerases,
the -a and -b isoforms. We have previously shown that both
topoisomerase IIa and -b form stabilised enzyme-DNA complexes
in the presence of drugs such as etoposide (Willmore et al., 1998).
It is possible though that the complexes formed with each isoform
are differentially distributed in the nucleus, differently affected by
pre-existing DNA damage (Bigioni et al., 1996; Kingma et al.,
1997; Wilstermann and Osheroff, 2001) or other cellular processes
such as transcription or replication (Mao et al., 2001; Niimi et al.,
2001), and/or that their resulting adducts are removed by different
mechanisms.
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While 59 phosphotyrosyl-linked topoisomerase must be
removed prior to DSB repair, the mechanism to achieve this
may differ depending on the context. For example, topoisomerase
II protein-DNA covalent complexes can form and be resolved in
G1, but are also present in S-phase and interfere with replication
leading to replication fork stalling, DSB generation, intra-S phase
checkpoint signalling and dispersal of replication proteins
(Kaufmann, 1998; Rossi et al., 2006). Processes implicated in
removal of 59-topoisomerase complexes involve: (1) a specific 59
tyrosyl DNA phoshodiesterase (TDP2) cleaving the
phosphodiester bond between the 59 phosphate and the tyrosine
(Cortes Ledesma et al., 2009; Zeng et al., 2011); (2) cleavage of
the DNA end bearing the topoisomerase II by a nuclease such as
MRE11 (Neale et al., 2005; Hartsuiker et al., 2009a); (3)
cleavage by an AP lyase activity such as Ku (Ayene et al., 2005;
Roberts et al., 2010); (4) a proteolytic mechanism (Mao et al.,
2001; Sunter et al., 2010), (5) or a sequential combination of
several of these activities.
Genetic studies in S. cerevisiae have provided a useful starting
point for human studies and support a role for MRE11 in the
removal of stabilised 59-topoisomerase II-DNA complexes
(Neale et al., 2005; Hartsuiker et al., 2009a). Mre11 is part of
the MR complex (Mre11/Rad50), which is involved in the
essential process of repairing double strand breaks and is
conserved through evolution. The MR complex associates with
NBS1 in humans (MRN complex) and Xrs in yeast (MRX
complex). Mre11 is a nuclease with both exonuclease and
endonuclease activities, the nuclease motifs are located in the N-
terminal domain and are evolutionarily highly conserved. The
single-strand endonuclease acts on a number of substrates
including 59 overhangs, 39 flaps, 39 branches and closed
hairpins. The 39–59 exonuclease acts on double stranded DNA
(D’Amours and Jackson, 2002). In vitro, the activity is highest in
the presence of manganese but magnesium also supports some
activity (Hopkins and Paull, 2008). In mammals the nuclease
activity of MRE11 is required for homology directed double
strand break repair, but the nuclease function is not required for
ATM activation after DNA damage or telomere deprotection
(Buis et al., 2008).
During meiosis a topoisomerase II like protein, Sporulation 11
(Spo11) is required to introduce double strand breaks. Unlike
topoisomerase II, which normally re-ligates the transiently
cleaved double stranded DNA (dsDNA), Spo11 is
endonucleolytically removed from the 59-end of the cleaved
DNA revealing free DNA strands allowing meiotic
recombination to take place, and releasing Spo11 attached to
an oligonucleotide with a free 39-end (Neale et al., 2005). In
budding yeast two different Spo11-oligonucleotide complexes
are produced; this was an important observation suggesting the
DSB ends were biochemically distinct with asymmetric cleavage
at each DSB. Notably, this removal of Spo11 requires the
nuclease activity of the MRX complex and its functional partner,
Sae2/Ctp1 in budding and fission yeast (Neale et al., 2005;
Hartsuiker et al., 2009b; Cole et al., 2010).
Topoisomerase II-oligonucleotide complexes were also
isolated from vegetative S. cerevisiae, but these were not
genetically dependent upon MRE11 and SAE2 and the
significance of these complexes is not known. Functional
redundancy between nucleases has been proposed and possible
nucleases include Sae2/Ctp1, Exo1 and Dna2 (Nicolette et al.,
2010). In S. pombe Mre11 nuclease-dead or Ctp1 null strains are
both hypersensitive to the etoposide derivative Top53 and the
levels of covalent topoisomerase II-DNA complexes induced in
these strains are approximately two fold higher than in wild type
cells, implicating Mre11 and Ctp1 in removal of topoisomerase II
covalent complexes (Malik and Nitiss, 2004; Hartsuiker et al.,
2009a). Extending this analysis to bacterial and bacteriophage
systems, the E. coli MR complex, SbcCD is able to remove an
avidin protein adduct in vitro (Connelly and Leach, 2004) and the
T4 endonuclease VII was shown to remove topoisomerase II
complexes at stalled replication forks in vitro and in vivo (Hong
and Kreuzer, 2003).
A number of studies also implicate MRE11 in the removal of
topoisomerase II complexes in human cells. For instance, during
adenovirus infections in human cells, the 59-end of the linear
viral genome is protected by a terminal protein. Without this
protein viral DNA is joined into concatemers too large to be
packaged effectively. However, in the presence of MRE11,
RAD50 and NBS1 (which localise in foci next to viral replication
centres) this protein is removed preventing viral packaging. Part
of the viral defence mechanism, is to both degrade and reorganise
the expression of the MRN complex (Stracker et al., 2002). In
addition, a role for the MRN complex in processing
topoisomerase II lesions has been suggested by the fact that
murine cells with mutated Rad50 show elevated sensitivity to
etoposide (Morales et al., 2008).
The precise role of the MR complex in processing
topoisomerase II covalent DNA complexes is not clear. The
nuclease activity of MRE11 may directly remove DNA bearing
the covalently attached topoisomerase II adduct or it may play a
role as a DNA damage sensor and signal transducer to activate a
component downstream of the MR complex and trigger removal
of the DNA adduct (Connelly and Leach, 2004).
We previously developed the trapped in agarose DNA
immunostaining (TARDIS) assay to detect topoisomerase
complexes formed in individual live cells on genomic DNA
(Willmore et al., 1998). Cells are embedded in agarose and the
cellular membranes and non-covalently bound proteins are
removed; the covalently bound topoisomerase II remains on the
DNA and can be visualised by immunofluorescence and
quantified (Willmore et al., 1998; Cowell et al., 2011a). We
have used this methodology to generate genomic DNA bearing 59
topoisomerase II drug stabilised cleavage complexes. Using this
as a substrate, we show that MRE11 can remove topoisomerase
II-DNA complexes from genomic DNA in vitro. We also show
that MRE11 plays a role in the maintaining low basal levels of
topoisomerase II complexes in cells.
Results
Adaption of the TARDIS assay
To determine if MRE11 has a role in removing human
topoisomerase II from DNA, we have modified the TARDIS
assay. The TARDIS assay has previously been used extensively
to study the kinetics of formation and removal of topoisomerase
II complexes within cells (Cowell et al., 2011a). Here we have
adapted the method to use the TARDIS slides as a source of non-
recombinant topoisomerase II protein covalently attached to
genomic DNA. K562 leukaemia cells were treated with 100 mM
etoposide to generate genomic DNA bearing covalent
topoisomerase II protein-DNA complexes. The cells were then
embedded in agarose and lysed to remove non-covalently bound
cellular proteins including histones. We refer to this in vitro
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substrate of genomic DNA bearing topoisomerase II complexes
on slides, as DNA-topoisomerase II adducts, to distinguish them
from complexes modulated within cells and then analysed on
slides. The slides bearing the topoisomerase II adducts were
incubated with immunoprecipitates or purified protein, and
then washed prior to immunofluorescent visualisation and
quantification steps (Fig. 1A). Non-specific proteolysis that
could remove the protein signal was prevented by adding a
cocktail of protease inhibitors to the buffers. Adducts were
detected using anti-topoisomerase II antisera and visualised with
an FITC labelled secondary antibody. An outline of the assay is
shown in Fig. 1A. Data were obtained for large numbers of
individual cells and the data are either shown in scattergrams
where each point represents a single nucleus, or as histograms
where the mean and standard error of the mean are shown.
Experiments were normalised to the positive control (100 mM
etoposide, no post-treatment), which was set at 100%. This
adaption of the trapped in agarose DNA immunostaining assay was
validated by showing that incubation with proteinase K resulted in
a significant drop in the topoisomerase II immunofluorescence
signal. With proteinase K the reduction for topoisomerase IIa was
68%60.5, whilst for topoisomerase IIb the reduction was
87%60.3. Proteinase K did not remove DNA from the slides as
determined by Hoechst fluorescence (Fig. 1B,C). Incubation with
200 units of purified mung bean nuclease removed DNA but not
topoisomerase II protein (Fig. 1B,C).
MRE11 immunoprecipitates remove topoisomerase II adducts
in vitro
Immunoprecipitation was used to obtain non-recombinant, native
human MRE11. MRE11 was immunoprecipitated from whole
cell extracts of K562 leukaemia cells. The presence of MRE11 in
the immunoprecipitate was confirmed by Western blotting
(Fig. 2A) and mass spectrometry (supplementary material Fig.
S1). Mass spectrometry indicated the immunoprecipitate also
contained RAD50, but NBS1, CTIP, EXO1, DNA2, TDP1 or
TDP2 were not detectable by mass spectrometry. Slides
containing genomic DNA bearing topoisomerase II adducts
derived from K562 cells treated with 100 mM etoposide were
incubated with MRE11 immunoprecipitates from K562 cells
for 90 minutes at 37 C˚. The slides were then washed and
topoisomerase II adducts visualised and quantified by immuno-
fluorescence. Topoisomerase IIa adducts were partially removed,
with 45% reduction in FITC signal, in contrast an increase in
topoisomerase IIb FITC signal was seen (Fig. 2). As a control,
Fig. 1. Use of TARDIS to assay activities capable of removing
topoisomerase II covalent DNA complexes from genomic DNA. (A) Scheme
of assay method. The TARDIS assay allows quantitative assessment of
topoisomerase II-DNA covalent complexes that are formed in vivo on genomic
DNA (Willmore et al., 1998; Cowell et al., 2011a). Cells treated with
topoisomerase poison (in this case 100 mM etoposide) are embedded in agarose
and spread onto a microscope slide. After salt/detergent extraction of soluble
components, covalently bound topoisomerase II remaining in the embedded
genomic DNA is detected by immunofluorescence. To assay for components
capable of removing topoisomerase II covalent DNA complexes, slides are
incubated with extracts or purified proteins, before antibody probing and
immunofluorescence (see Materials and Methods). (B,C) Validation of assay.
K562 cells were either untreated (first column) or treated with etoposide
(100 mM, 2 hr, columns 2–6). After extraction slides were either untreated or
treated as shown with mung bean nuclease (MB) or proteinase K (PK) in the
relevant buffer or with buffer alone, prior to immunofluorescence. Mean values
of integrated fluorescence per nucleus were determined and the mean of all the
cells analysed is shown 6 standard error of the mean. All treatments were
normalised to the mean values obtained for cells treated with 100 mM etoposide
alone. Left graph, Hoechst fluorescence for DNA content; right graph, FITC
fluorescence for remaining topoisomerase II. *** 5 p value ,0.0001.
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MRE11 was immunodepleted from the MRE11 immunoprecipi-
tate (Costanzo et al., 2004); following MRE11 immunodepletion
the topoisomerase IIa adduct removal activity was reduced to
only 9% removal. Other controls included immunoprecipitation
with no antisera or whole IgG. Neither of these control
immunoprecipitates removed as much topoisomerase IIa as the
MRE11 immunoprecipitate (Fig. 2). In ten replicate experiments
topoisomerase IIa adducts were partially removed by MRE11
immunoprecipitates from K562 cells, but topoisomerase IIb was
not removed by the same MRE11 immunoprecipitates, indeed the
signal increased. The MRE11 immunoprecipitate reduced the
Hoechst signal (supplementary material Fig. S2) as did the IgG
control immunoprecipitate. The adduct removal activity was
dependent upon divalent metal ions as 20 mM EDTA abolished
the topoisomerase II adduct reduction by the MRE11 immuno-
precipitate (data not shown). The simplest explanation of these
results is that the immunoprecipitated MRE11 is responsible for
the TOP2A adduct removal; however, we cannot totally exclude
the possibility that the MRE11 immunoprecipitate contains a co
precipitating metal ion dependent activity responsible for
removing topoisomerase IIa, therefore we looked at purified
recombinant MRE11.
Recombinant MRE11 removes topoisomerase IIa adducts
in vitro
To determine whether recombinant MRE11 could remove
etoposide stabilised topoisomerase II adducts from genomic
DNA in vitro we incubated slides bearing topoisomerase II
adducts on genomic DNA with recombinant MRE11. Human
recombinant MRE11 residues 1–206 encompassing the nuclease
domain fused to GST was obtained from Abnova. In addition,
TmMre11 from Thermotoga maritima was analysed. Wild type
and three mutated forms of TmMre11 were used, one nuclease
dead form TmMre11 H94S and two partially active forms
TmMre11 H61S and TmMre11 H180S (Das et al., 2010).
A commassie stained gel, an in gel nuclease and Western of
the truncated MRE11 from Abnova is shown in Fig. 3A. There
was no evidence of any contaminating nucleases. Recombinant
human truncated MRE11 removed 49% of non-recombinant
human etoposide-stabilised topoisomerase IIa adducts from
genomic DNA in vitro (Fig. 3B), but only 7% of the human
topoisomerase IIb adducts (Fig. 3C). Inclusion of mirin, an
inhibitor of the nuclease activity of MRE11 (Dupre´ et al., 2008;
Garner et al., 2009) significantly reduced the adduct removal
(Fig. 3B,C). Addition of EDTA abolished adduct removal
supporting the idea that the adduct removal is via a cation
dependent nuclease (supplementary material Fig. S3). The
Fig. 2. Immunopurified MRE11 removes topoisomerase IIa covalent
complexes from genomic DNA. (A) Western blot probing K562 whole cell
extract, K562 MRE11 immunoprecipitate and IgG and no antibody control
immunoprecipitates for MRE11 (B,C) K562 cells were treated with 100 mM
etoposide for two hours prior to embedding in agarose on microscope slides.
The slides were incubated with various immunoprecipitates, the fluorescence
levels for the topoisomerase II covalent complexes remaining after the
incubations were measured, the fluorescence value for each nucleus was
determined and normalised to the mean of the positive control incubated in
buffer (100%). These are shown as percentage of FITC signal remaining on a
slide after incubation with MRE11 IP 5 eluted components from MRE11 IP;
Depl MRE11 IP 5 immunodepleted MRE 11 IP eluate, Ig cont IP 5 IgG
control IP, No Ab cont IP 5 control IP without antibody.
*** 5 p value ,0.0001.
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recombinant truncated MRE11 did not remove DNA from the
slides, as judged by Hoechst fluorescence (Fig. 3D,E). This
truncated MRE11 was unable to remove 59phosphotyrosine from
an oligonucleotide, indicating that it is not acting as a tyrosyl
phosphodiesterase (data not shown).
Wild type recombinant Mre11 from Thermotoga maritima, and
three different mutated forms of TmMre11 protein were also
studied (Fig. 4A) (Das et al., 2010). The three mutated proteins
were TmMre11 H94S an endonuclease dead protein and
TmMre11 H61S and H180S mutations that result in partial loss
of function (Fig. 4B), consistent with analogous mutations in
Pyrococcus furiosus and fission yeast Mre11 (Williams et al.,
2008; Das et al., 2010). These proteins were applied to slides
bearing etoposide stabilised covalent DNA-topoisomerase II
adducts (Fig. 4). Like human MRE11, wild type TmMre11
removed a proportion of human topoisomerase IIa adducts from
genomic DNA and the TmMre11 H180S protein also removed
some topoisomerase IIa but less than wild type TmMre11. None
of the four variants of TmMre11 removed human topoisomerase
IIb etoposide stabilised adducts under these conditions (Fig. 4D).
A-TLD cells
As a human cell line model for the role of MRE11, we used A-
TLD fibroblasts derived from a 20 year old male patient with
Ataxia-Telangiectasia-Like Disorder 2 now referred to as A-
TLD(S). These cells are homozygous for an MRE11 allele where
codon 633 is altered to a stop codon, resulting in a truncated
MRE11 protein with a molecular weight of 72 kDa rather than
full-length, wild type MRE11 protein with a molecular weight of
81 kDa. The truncated protein retains a functional nuclease
domain, but its cellular distribution is different to that of full-
length MRE11, as it does not form a functional MRN complex
(supplementary material Fig. S4) (Uziel et al., 2003; Stewart
et al., 1999). In addition to immortalised A-TLD cells (A-TLD
hTERT) (Uziel et al., 2003) we employed three isogenic variants
A-TLD wtMRE11, A-TLD mre3 and
A-TLD GFP which had been transduced with retroviruses
expressing wild-type MRE11, MRE11-3 or GFP respectively
(Fig. 5A; supplementary material Fig. S4). The mre3 protein is
nuclease deficient due to amino acid changes in the phospho-
diesterase domain III at positions 129 and 130 (Arthur et al.,
Fig. 3. Purified recombinant MRE11 removes
topoisomerase IIa covalent complexes from genomic
DNA. (A). Coommassie, in-gel nuclease and Western
analysis of recombinant MRE11. (B–E) K562 cells were
treated with 100 mM etoposide for two hours. Slides
bearing agarose-embedded cells (1–26106 cells in 100 ml
1% agarose in PBS spread across the slide surface) were
incubated with MRE11 buffer or 1 mg MRE11 in MRE11
buffer in the presence or absence of the MRE11 nuclease
inhibitor mirin and quantitative immunofluorescence was
carried out for topoisomerase IIa or -b. (B,C) The mean
FITC fluorescence for each nucleus was normalised to the
100 mM etoposide positive control, and the mean6SEM are
shown. *** 5 p value, 0.0001, * 5 p value ,0.05.
(D,E) The mean hoechst fluorescence for each nucleus was
normalised to the positive control, and the mean6SEM
are shown.
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2004). Western blotting confirmed that the control cells did not
express full-length MRE11 and that the A-TLD cells lines
transduced with the full-length MRE11 or mre3 contained a full-
length MRE11 protein in addition to the truncated protein
(Fig. 5B). The full-length nuclease-deficient protein has pre-
viously been shown to adopt the correct sub-cellular localisation
pattern (Stewart et al., 1999; Uziel et al., 2003; Arthur et al.,
2004). We confirmed by immunofluorescence that the truncated
MRE11 in the A-TLD hTERT cells has a largely cytoplasmic
distribution, in contrast to the nuclear distribution of the wild
type MRE11 in the transduced cells (supplementary material Fig.
S4). Although the nuclease activity is abrogated in the mre3
protein, a heterodimer with the nuclease-functional 72 kDa
protein would produce a functional MRN complex with nuclease
activity, albeit half that of a homodimer of full length wild type
protein. All these A-TLD cells grew very slowly in culture.
MRE11 immunoprecipitates were prepared from three A-TLD
cell lines, A-TLD-GFP, A-TLD-wtMRE11 and A-TLD-mre3
(Fig. 5C). To analyse whether these immunoprecipitates were
able to remove drug stabilised topoisomerase II adducts from
DNA in vitro, we used the adapted TARDIS assay described
previously. Incubation with MRE11 immunoprecipitates from any
of the three A-TLD cell types resulted in significantly reduced
topoisomerase IIa (P#0.0001) but no reduction in topoisomerase
IIb adduct levels, similar to the results obtained with K562
immunoprecipitates (Fig. 2). As expected the MRE11
immunoprecipitate from the A-TLDwtMRE11 reduced the
etoposide stabilised topoisomerase IIa adduct levels to a
greater extent than those from the A-TLDmre3 or A-TLD cell
lines. Nevertheless, substantial adduct removal was observed
with immunoprecipitates from each A-TLD cell line, including
A-TLD-GFP which expresses no full-length MRE11. However,
the immunoprecipitations were carried out from whole cell
lysates, and thus the cytoplasmic nuclease proficient truncated
MRE11 present in all three A-TLD cell lines used will be
captured by the immunoprecipitation protocol (supplementary
material Fig. S4).
A-TLD cells have high background levels of topoisomerase
II complexes
Topoisomerase IIa complex levels within A-TLD cells were
analysed to determine whether dysfunctional cellular MRE11
affects the level of topoisomerase IIa complexes within cells. In
preliminary experiments we noticed that the basal level of
topoisomerase IIa adducts in A-TLD cells was very high.
Subsequently, A-TLD cells were treated with etoposide or
vehicle and the topoisomerase II complex levels within the A-
TLD cells were visualised using the TARDIS assay. A number of
replicate experiments were performed for A-TLD wt MRE11
(n56), A-TLD (n59) and A-TLD mre3 (n53) cells. In each case
fluorescence values were normalised, setting the treatment with
100 mM etoposide for 2 hours as 100%. The level of
topoisomerase IIa complexes in the absence of etoposide were
very high in the A-TLD cells lacking wild type MRE11
(Fig. 5D), whilst the A-TLDwtMRE11 cells contained
significantly lower levels of complexes.
We have previously noted that following etoposide
treatment, the initial high level of topoisomerase IIa DNA
covalent complexes that are detected by TARDIS falls rapidly
when drug is removed (Errington et al., 2004). This is due
either to processing of the complexes and repair or completion
of the reaction cycle and resolution of the complexes following
reversal of topoisomerase-etoposide interaction. We measured
topoisomerase IIa complex levels in A-TLD cells at different
time points following treatment with and removal of etoposide
(Fig. 5E). In the A-TLDwtMRE11 cells, which contain
functional MRE11 the topoisomerase II complex levels
reduced as did those in K562 cells. The level of complexes
in the A-TLDmre3 decreased but more slowly. It should be
borne in mind that the A-TLDmre3 cells also express truncated
nuclease proficient MRE11 with which it can heterodimerize
(Fig. 5A), reconstituting a functional MRE11 activity. In
contrast, the complexes in the A-TLD cells remained high,
consistent with the very high levels of topoisomerase
complexes in these cells prior to etoposide exposure. These
Fig. 4. Purified recombinant MRE11 from Thermotoga
maritima removes topoisomerase IIa covalent complexes
from genomic DNA. Purified recombinant MRE11 from
Thermotoga maritima (A) SDS-PAGE of TmMre11,
TmMre11H94S, TmMre11H61S or TmMre11H180S
proteins. (B) Endonuclease assays were performed with
single-stranded bacteriophage QX174 DNA as a substrate
with TmMre11, TmMre11H94S, TmMre11H61S or
TmMre11H180S. K562 cells were treated with 100 mM
etoposide for two hours prior to being embedded in agarose
on microscope slides. Slides bearing agarose-embedded
cells (1–26106 cells in 100 ml 1% agarose in PBS spread
across the slide surface) were incubated with MRE11 buffer
(positive control) or 1 mg TmMre11, TmMre11H94S,
TmMre11H61S or TmMre11H180S. Quantitative
immunofluorescence was carried out for topoisomerase IIa
(C) or -b (D). The mean fluorescence for each nucleus was
normalised to the positive control, and the mean6SEM are
shown. *** 5 p value, 0.0001.
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data imply that cells lacking functional MRE11 accumulate
topoisomerase-DNA covalent complexes in the absence of
drug, either through an increased rate of production or
decreased rate of resolution.
Inhibition of MRE11 nuclease increases topoisomerase II
complex levels
To address whether it is a lack of nuclease activity that leads to
increased topoisomerase complex levels in cells we treated K562
Fig. 5. See next page for legend.
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cells with mirin, a small molecule inhibitor of MRE11 nuclease
activity. Inhibiting MRE11 nuclease activity for 24 hours
significantly increased the background levels of topoisomerase
IIa complexes and topoisomerase IIb complexes (Fig. 6).
Inhibition of replication increases topoisomerase II
complex levels
MRE11 has been reported to be important for the restart of stalled
replication forks in association with PARP (Robison et al., 2004;
Bryant et al., 2009) and notably, inhibition of PARP increased the
topoisomerase II complex levels in the absence of topoisomerase
poison, as did inhibition of ATM in the TARDIS assay (data not
shown). This led us to consider whether the elevated cellular
topoisomerase II complex levels associated with MRE11
deficiency in cells is related to replication stress. To test if
stalled replication forks cause the increase in topoisomerase II
complexes, we treated cells with hydroxyurea (HU), which leads
to replication stress through depletion of nucleotide pools. HU
affects both initiation and elongation in replication and average
rates of replication are reduced. HU generates stalled replication
forks, which on prolonged exposure convert to DSBs, also
extensive single-stranded regions accumulate in the presence of
HU. Topoisomerase IIa and -b covalent complex levels increased
following HU treatment (Fig. 7). Not all forms of replication
stress increased topoisomerase II complex levels as the
topoisomerase I poison camptothecin, which generates
replication stress through collision of replisomes with CPT-
stabilised topoisomerase I complexes, blocking replication fork
progression (Furuta et al., 2003) did not lead to elevation of
topoisomerase II complex levels.
Discussion
MRE11 immunoprecipitates containing non-recombinant
MRE11 removed etoposide-stabilised topoisomerase IIa protein
adducts from genomic DNA in vitro, immunodepletion of
immunoprecipitates reduced adduct removal. Thus, MRE11 or
something that co-precipitates with it is able to remove etoposide
stabilised topoisomerase IIa adducts from genomic DNA
(Fig. 2). Addition of EDTA abolished this activity, indicating
the activity was dependent upon divalent cations. The same
immunoprecipitates and in vitro incubation conditions did not
decrease the topoisomerase IIb complexes, in fact the
immunofluorescent signal increased. This may be due to
increased accessibility to the anti-topoisomerase IIb antisera
following detergent and salt treatment of heterochromatin
(Cowell et al., 2011b). Etoposide stabilised topoisomerase II
adducts were also removed from genomic DNA in vitro by
recombinant MRE11, 49% of the topoisomerase IIa adducts were
removed (P.0.0001), but only 7% of the topoisomerase IIb
complexes (p50.0302). This activity was again abolished by
EDTA. The MRE11 nuclease inhibitor mirin prevented MRE11-
mediated in vitro topoisomerase IIa adduct removal, confirming
the removal was via MRE11 nuclease activity (Fig. 3). In
addition, TmMre11 removed etoposide stabilised topoisomerase
IIa adducts (Fig. 4). These data strongly support a role for
MRE11 nuclease activity in removing etoposide stabilised
topoisomerase IIa adducts by cleaving the DNA to remove the
protein adduct and a fragment of DNA, analogous to MRE11’s
role in removing SPO11 (Lange et al., 2011).
Fig. 5. Functional MRE11 is required to maintain low topoisomerase II covalent complex levels. (A) Schematic of the MRE11 variants expressed in the
respective A-TLD cell lines. (B) Western blot showing the full length MRE11 in K562 whole cell extracts, full length and 72 kDa MRE11 in A-TLDmre-3 whole cell
extract and only the truncated 72 KDa MRE11 in A-TLD whole cell extracts. (C) K562 cells were treated with 100 mM etoposide or vehicle alone. Cells were
prepared for TARDIS analysis as described in Fig. 1 and slides were treated with IP eluates from cells expressing the MRE11 variants shown (columns 3–5 of each
graph). Topoisomerase II immunofluorescence was measured and mean values for each nucleus were normalised to the mean signal obtained with 100 mM etoposide
with no IP treatment, the mean of the cell means is shown 6SEM. (D,E) Topoisomerase IIa complex levels were determined by TARDIS assay in A-TLD (s) cells.
The levels of complexes in the cells were determined in the absence and presence of etoposide. The mean level of complexes as determined by FITC fluorescence,
with 100 mM etoposide was set at 100% for each cell line. (D). The untreated control levels are shown for each of the 3 A-TLD cell lines. For comparison the levels in
untreated K562 cells are also shown as a percentage of the signal obtained in cells treated with 100 mM etoposide. (E) Change in topoisomerase IIa complex levels in
cells, indicative of the rate of removal of the complexes are shown for K562, A-TLDwtMRE11, A-TLDmre-3 and A-TLD cells following removal from medium
containing etoposide. *** 5 p value, 0.0001.
Fig. 6. The MRE11 nuclease inhibitor mirin increases topoisomerase II
DNA covalent complexes. K562 cells were exposed to mirin for 24 hours at
the concentrations shown and topoisomerase II complexes were quantified by
TARDIS. Mann-Whitney significance values are shown. ***5 p value, 0.0001.
Fig. 7. Hydroxyurea exposure leads to elevated topoisomerase II DNA
covalent complex levels. K562 cells were treated with etoposide for 2 hours
(Etop), hydroxyurea for 18 hours (HU) or camptothecin for 18 hours (CPT).
Topoisomerase II levels were measured by TARDIS. Mean fluorescence
signals were normalised to the mean level obtained with 100 mM etoposide.
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In contrast to the in vitro situation where recombinant MRE11
protein removed topoisomerase IIa etoposide stabilised
complexes much more efficiently than topoisomerase IIb (49%
removal compared to 7% removal), lack of MRE11 activity
within cells led to comparable increases in topoisomerase IIa and
b complexes in the absence of etoposide. A-TLD cells, which
have a truncated MRE11 that does not form an MRN complex,
exhibited very high basal levels of topoisomerase II complexes.
These high basal levels of complexes were substantially reduced
when A-TLD cells were transduced with wild type MRE11
(Fig. 5D). Consistent with this, inhibition of MRE11 in K562
cells by inclusion of mirin in the culture medium substantially
increased the normally low basal level of topoisomerase II
complexes detected by TARDIS assay in this cell line, 100 mM
mirin produced a 50% increase in the mean FITC signal for both
isoforms compared to the untreated cells (Fig. 6). These data
strongly suggest that MRE11 is in some way necessary for
homeostasis of topoisomerase II-DNA complexes that arise as
part of normal cellular metabolism, in the absence of drugs. The
source of these complexes in the absence of etoposide is not yet
clear. Abasic sites represent one candidate trigger for
topoisomerase II complexes resulting from normal cellular
metabolism (Wilstermann and Osheroff, 2001). Complexes
arising during cellular metabolism may represent a substrate for
MRE11-dependent processing, and thus lack of MRE11 activity
would raise basal topoisomerase II complex levels in A-TLD
cells (Fig. 5) and after mirin treatment of K562 cells (Fig. 6).
Alternatively replication stress and stalled replication forks
may trigger generation of abortive topoisomerase II complexes.
MRE11 nuclease activity is required for replication fork restart in
conjunction with PARP (Robison et al., 2004; Bryant et al., 2009)
and MRE11 co-localizes with proliferating cell nuclear antigen
(PCNA) throughout S phase and appears to be loaded onto
chromatin at the replication fork. Also MRE11 is localised to
single stranded regions in hydroxyurea treated cells (Mirzoeva
and Petrini, 2003), and can degrade stalled forks in an activity
blocked by mirin (Schlacher et al., 2011). Topoisomerase II also
co-localizes with PCNA (Niimi et al., 2001; Gilljam et al., 2009)
and is associated with nascent DNA (Qiu et al., 1996). In support
of the idea that stalled replication forks may trigger generation of
abortive topoisomerase II complexes, we found that treatment of
K562 cells with HU generated a topoisomerase IIa and b signal
comparable to or greater than that obtained when cells were
treated with etoposide (Fig. 7).
59-phosphotyrosyl-linked topoisomerase protein arising from
enzyme poisoning or through spontaneous abortive cleavage
reactions is a potentially lethal obstacle to DNA repair and to
cellular processes including transcription and replication.
Evidence exists for more than one pathway to remove such
complexes. Support for the involvement of MRE11 together with
CtIP in processing topoisomerase II DNA complexes derives
from genetic studies in yeast (Neale et al., 2005; Hartsuiker et al.,
2009a) and in mammalian cells (Nakamura et al., 2010; Quennet
et al., 2011). Here we show for the first time that MRE11 can
remove topoisomerase IIa complexes from DNA in vitro, and
that this is dependent on MRE11 nuclease activity (Figs 3, 4).
Since genetic or inhibitor induced MRE11 nuclease deficiency
leads to elevated basal topoisomerase II-DNA complexes in
cultured cells (Figs 5, 6), we suggest that an MRE11 dependent
pathway is involved in removing topoisomerase II complexes that
arise through cellular metabolism.
Materials and Methods
Cell culture
The K562 cell line was derived from a patient with chronic myelogenous leukemia
(CML) in terminal blast phase and its metabolism is therefore similar to that of
AML blasts. Cells were maintained as a suspension culture in RPMI 1640 medium
supplemented with 10% (v/v) fetal bovine serum, penicillin (50 U/ml), and
streptomycin (50 mg/ml) and were grown at concentrations between 16105 and
16106/mL and were free of mycoplasma contamination. The doubling time of the
cells was approximately 24 hours (K562). A-TLD cells were kindly supplied by
Yosef Shiloh and Yaniv Lerenthal, these cells were fibroblasts derived from a 20
year old male patient with Ataxia-Telangiectasia-Like Disorder 2 now referred to
as A-TLD(S). They are homozygous for a truncated version of MRE11 72 kDa
(residue 633 altered to a stop codon) rather than full-length 81 kDa MRE11. These
cells are hypomorphic, express truncated protein and they are genetically unstable.
The lifespan of primary A-TLD fibroblasts is short, so primary A-TLD(S) cells
were immortalised by ectopic expression of the catalytic subunit of human
telomerase (hTERT). These immortalised cells were then transduced with a
retroviral vector expressing recombinant wild type MRE11. In the transduced cells
the MRE11 co-localised with RAD50 and NBS1, suggesting reassembly of the
nuclear MRN complex. A-TLD mre3 cells were transduced with nuclease deficient
version of the MRE11 protein that still formed an MRN complex, but the nuclease
activity was completely abrogated. Cell culture reagents were obtained from
Invitrogen (Paisley, UK).
Drugs
Etoposide was dissolved in methanol as a 2 mM stock and was purchased from
Sigma (Poole, Dorset, UK). Mirin was dissolved in DMSO, it was supplied by
Alan Eastman or Biomol. Hydroxyurea was purchased from Sigma (Poole, Dorset,
UK).
Recombinant MRE11
Human MRE11 amino acids 1–206 fused to GST was purchased from Abnova
(H00004361-P01) (Taipei, Taiwan).
Wild type and three mutated forms of TmMre11 protein from eubacteria
Thermotoga maritima was produced as detailed in (Das et al., 2010). In TmMre11
H94S is an endonuclease dead protein, whilst TmMre11 H61S and H180S are
partially active (Das et al., 2010).
Antibodies
The anti-topoisomerase II polyclonal antibodies used in these studies were raised
in rabbits. Antibody 18511 was raised to recombinant human topoisomerase IIa
and antibody 18513 to a recombinant carboxyl-terminal fragment of human
topoisomerase IIb. Western blots demonstrated that 18511 detected the a isoform
specifically and 18513 detected the b isoform specifically (Cowell et al., 1998).
In the TARDIS assays, 18511(a) was used at a 1:50 dilution and 18513 (b) at
1:150. The anti-rabbit FITC-conjugated second antibody (F(ab9)2 fragment
(Sigma, Poole, Dorset, UK) was used at 1:100 dilution. MRE11 antibody (ab397)
(Abcam) was a rabbit polyclonal, raised to human MRE11 (full length) fusion
protein.
Immunoprecipitations
Cell pellets containing 1.66108 cells per ml were resuspended in RIPA buffer
(phosphate-buffered saline (PBS) with 1% (v/v) NP-40, 0.5% (w/v) sodium
deoxycholate, 0.1% (w/v) sodium dodecyl sulphate (SDS) and 10% DNase 1 in
0.15 M NaCl), at 4 C˚. The cell pellet was then centrifuged at 18,000 6g for
10 minutes and the cell supernatant removed. 100 ml of protein A sepharose beads
(GE Healthcare, Little Chalfont, Bucks, UK) was added to the supernatant and
incubated for 1 hour. The solution was centrifuged at 18,0006g for 10 seconds
and supernatant removed. 3 ml of MRE11 antibody ab397 was added to the
supernatant and incubated for 2 hours. Next, 600 ml of protein A sepharose beads
(GE Healthcare, Little Chalfont, Bucks, UK) were added and incubated for
2 hours. The solution was centrifuged at 18,000 6g for 10 seconds and the
supernatant removed. The beads with bound protein, were washed three times with
PBS plus protease inhibitors (2 mg/ml pepstatin A, 2 mg/ml leupeptin, 1 mM
phenyl methyl sulphonyl fluoride, 1 mM benzamidine) and 1 mM DTT. The
washed beads were stored at 280 C˚. Proteins were extracted from the beads and
dialysed. 0.1 M glycine (pH 3) was added to the samples for five minutes, to
displace the protein from the protein A sepharose beads. The solution was
centrifuged for 10 seconds and the supernatant removed. 6.96elution buffer (5 M
Tris, 414 mM KCl, 6.9 mM MnCl2 and 1.38% (v/v) Tween 20) plus 0.1% (w/v)
DTT and protease inhibitors (2 mg/ml pepstatin A, 2 mg/ml leupeptin, 1 mM
phenyl methyl sulphonyl fluoride, 1 mM benzamidine) were added to the
supernatant. In-gel nuclease assays showed no detectable contaminating nuclease
activity in the Mre11 immunoprecipitate. These immunoprecipitates were used in
TARDIS assays as detailed in the results.
MRE11 complexes 871
B
io
lo
g
y
O
p
e
n
TARDIS assay
TARDIS assays were performed as described previously (Willmore et al., 1998;
Cowell et al., 2011a). Briefly, images were taken on an Olympus IX81 microscope
system with a Hamamatsu Orca-AG camera. Captured microscopy images were
analysed by Volocity 64 software (Perkin Elmer). Statistical analysis was carried
out using GraphPad Prism software (Cherwell Scientific, Oxford, UK). Statistical
analysis (t-test and p-value) utilised the two tailed Mann-Whitney test. The mean
fluorescence signal for cells incubated with 100 mM etoposide was used as a
positive control in each experiment. The integrated fluorescence signal from
individual cells was normalised to the positive control mean. The total number of
cells analysed is shown in the figures.
For assays to quantify removal of topoisomerase adducts from genomic DNA,
slides bearing agarose-embedded cells were incubated for 90 minutes at 37 C˚ with
the immunoprecipitate (extracted from 8.56107 cells per slide) or purified proteins
described in the text or with the following buffers: MB buffer (50 mM potassium
acetate, 20 mM Tris-acetate, 10 mM Magnesium acetate, 1 mM DTT, pH 7.9);
PK buffer (30 mM Tris-HCl, pH 8.0); MRE11 buffer (25 mM MOPS pH 7.0,
60 mM KCl, 5 mM MnCl2, 2 mM DTT, 0.2% Tween 20).
Western blotting
Western blots were carried out by standard procedures using ECL detection (GE
Healthcare).
In-gel nuclease assay
12.5% SDS-PAGE gels were prepared containing 200 mg/ml denatured salmon
sperm DNA. MRE11 (1 mg) was run along with a positive control of 5 mg of
DNaseI. After electrophoresis gels were left overnight at 4 C˚ in 50 mM Tris-HCl
pH 7.5 and 1 mM EDTA. Gels were washed washes in fresh 50 mM Tris-HCl
pH 7.5 for 20 minutes at room temperature and then in the same buffer at 37 C˚.
Gels were then incubated in MRE11 buffer containing ethidium bromide (25 mM
MOPS pH 7.0, 60 mM KCl, 0.2% Tween 20, 5 mMMnCl2, 2 mM DTT, 0.5 mg/ml
EtBr) for 4 hours at 37 C˚ and then visualized using a UV transilluminator.
Endonuclease assays
Endonuclease assays were performed with single-stranded bacteriophage QX174
DNA as a substrate as detailed in (Das et al., 2010).
Immunofluorescence (in support of supplementary material)
Immunofluorescence was carried out essentially as described by Cowell et al.,
2011b. MRE11 immunofluorescence was carried out using rabbit anti-AB397
(Abcam). Images were collected at 150 mm z-steps using an Olympus IX81
microscope fitted with an Orca AG greyscale camera and 606 NA0.95 oil
immersion objective. Extended-focus images are displayed.
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